Show simple item record

dc.identifier.urihttp://hdl.handle.net/11401/77161
dc.description.sponsorshipThis work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree.en_US
dc.formatMonograph
dc.format.mediumElectronic Resourceen_US
dc.language.isoen_US
dc.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dc.typeThesis
dcterms.abstractCancer is one of the most serious diseases of the world, leading to one of eight deaths. Although the medical advancements have contributed greatly to the decline of other diseases, treatments for cancer have remained only modestly effective. Traditional chemotherapeutics such as Taxol and Taxotere generally lack specificity, and repeated administration often leads to multi-drug resistance (MDR). To increase the efficacy and specificity of drugs, both the synthesis and evaluation of lead compounds and the development of drug delivery system are equally important. SB-T-1214 and three novel taxanes, SB-T-12301 and two of its analogues, were synthesized by the standard Ojima-Holton coupling protocol using the corresponding β -lactam and 7,10-dimethylated-10-DAB III and C-2 meta-methyl or fluorobenzoyl 7,10-dimethylated-10-DAB III. The β -lactam was obtained via two well-established synthetic routes: Staudinger [2+2] cycloaddition followed by enzymatic resolution protocol and the chiral ester enolate-imine cyclocondensation. In addition, tumor-targeting taxane-based drug conjugate was synthesized by using biotin as the tumor-targeting module and a self-immolative disulfide linker, which can be cleaved in cancer cells due to high concentration of glutathione. Biotin plays a critical role in many biological processes. It is greedily taken up by tumor cells through a process of receptor-mediated endocytosis (RME) to meet its need of fast growth and propagation. The receptors of biotin are highly overexpressed on the surface of tumor cells and making them a good target for tumor-targeting drug design.
dcterms.available2017-09-20T16:52:07Z
dcterms.contributorDrueckhammer, Daleen_US
dcterms.contributorOjima, Iwaoen_US
dcterms.contributorBoon, Elizabeth.en_US
dcterms.creatorWang, Changwei
dcterms.dateAccepted2017-09-20T16:52:07Z
dcterms.dateSubmitted2017-09-20T16:52:07Z
dcterms.descriptionDepartment of Chemistry.en_US
dcterms.extent169 pg.en_US
dcterms.formatMonograph
dcterms.formatApplication/PDFen_US
dcterms.identifierhttp://hdl.handle.net/11401/77161
dcterms.issued2013-12-01
dcterms.languageen_US
dcterms.provenanceMade available in DSpace on 2017-09-20T16:52:07Z (GMT). No. of bitstreams: 1 Wang_grad.sunysb_0771M_11547.pdf: 11726387 bytes, checksum: b19dad56100ffc6201747ba849ea6a71 (MD5) Previous issue date: 1en
dcterms.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dcterms.subjectcabazitaxel, SB-T-12301, taxane, tumor-targeting drug conjugates
dcterms.subjectChemistry
dcterms.titleSynthesis of SB-T-12301 Analogues and Tumor-Targeting Taxane-Based Drug Conjugates using Biotin as Tumor-Targeting Module
dcterms.typeThesis


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record